About this Research Topic
Although a remarkable progress has been made in the development of new therapies for cancer, these therapies have also introduced unexpected cardiovascular complications, which progressively lead to cardiotoxic effects (CTX) such as heart failure (HF).
The quality of life of these patients is poor, resulting in significant morbidity and mortality. To date, there is no definitive and effective treatment to prevent anthracyclines-induced CTX. Indeed, these patients are treated similarly to non-oncologic patients with HF. Overall, these are suboptimal and non-specific treatments.
There is an unmet medical need for therapeutic strategies able to prevent chemotherapy-induced cardiotoxicity (CIC), which is a frequent complication that limits the survival of oncologic patients.
Here, it´s proposed an ambitious program to change the conceptual framework used for the management of the cardio-oncological patient. The global aim will be detail novel molecular mechanisms related to CIC. Here, novel pharmacological target will be described to design pioneered therapies to treat or prevent CIC.
The research topic aims to investigate the complex interplay between tumor therapy and cardiotoxicity, focusing on understanding the molecular mechanisms underlying cardiac dysfunction in the context of cancer treatment.
Contributors are encouraged to explore and shed light on the potential signaling pathways and molecular networks connecting the tumor and myocardium, leading to cardiotoxicity. We aim to establish a consultation area that addresses an unmet medical need for a research in the areas of development of gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics for cardiotoxicity, pre-clinical target validation, safety/efficacy studies, and clinical trials.
Contributors are invited to address the following specific themes:
- Molecular Pathways: Elucidating the key molecular pathways involved in cardiotoxicity following tumor therapy.
- Tumor-Mycardium Interplay: Investigating the bidirectional signaling between tumors and the myocardium and its impact on cardiac function.
- Novel Therapeutic Targets: Exploring promising targets to protect and ameliorate myocardial dysfunction caused by cancer treatments.
- Drug Development and Repurposing: Evaluating the potential of novel oligonucleotide-based therapies and drug candidates in mitigating cardiotoxicity.
- Mechanistic Insights: Presenting in-depth mechanistic insights into the disruption of Ca2+ homeostasis and its role in cardiac dysfunction post-chemo.
- Clinical Perspectives: Addressing clinical observations and outcomes related to cardiotoxicity in cancer patients and potential treatment strategies.
Drug Metabolism and Transport welcomes submissions of the following article types: Clinical Trial, Correction, Data Report, Editorial, General Commentary, Hypothesis & Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Technology and Code.
The quality of life of these patients is poor, resulting in significant morbidity and mortality. To date, there is no definitive and effective treatment to prevent anthracyclines-induced CTX. Indeed, these patients are treated similarly to non-oncologic patients with HF. Overall, these are suboptimal and non-specific treatments.
There is an unmet medical need for therapeutic strategies able to prevent chemotherapy-induced cardiotoxicity (CIC), which is a frequent complication that limits the survival of oncologic patients.
Here, it´s proposed an ambitious program to change the conceptual framework used for the management of the cardio-oncological patient. The global aim will be detail novel molecular mechanisms related to CIC. Here, novel pharmacological target will be described to design pioneered therapies to treat or prevent CIC.
The research topic aims to investigate the complex interplay between tumor therapy and cardiotoxicity, focusing on understanding the molecular mechanisms underlying cardiac dysfunction in the context of cancer treatment.
Contributors are encouraged to explore and shed light on the potential signaling pathways and molecular networks connecting the tumor and myocardium, leading to cardiotoxicity. We aim to establish a consultation area that addresses an unmet medical need for a research in the areas of development of gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics for cardiotoxicity, pre-clinical target validation, safety/efficacy studies, and clinical trials.
Contributors are invited to address the following specific themes:
- Molecular Pathways: Elucidating the key molecular pathways involved in cardiotoxicity following tumor therapy.
- Tumor-Mycardium Interplay: Investigating the bidirectional signaling between tumors and the myocardium and its impact on cardiac function.
- Novel Therapeutic Targets: Exploring promising targets to protect and ameliorate myocardial dysfunction caused by cancer treatments.
- Drug Development and Repurposing: Evaluating the potential of novel oligonucleotide-based therapies and drug candidates in mitigating cardiotoxicity.
- Mechanistic Insights: Presenting in-depth mechanistic insights into the disruption of Ca2+ homeostasis and its role in cardiac dysfunction post-chemo.
- Clinical Perspectives: Addressing clinical observations and outcomes related to cardiotoxicity in cancer patients and potential treatment strategies.
Drug Metabolism and Transport welcomes submissions of the following article types: Clinical Trial, Correction, Data Report, Editorial, General Commentary, Hypothesis & Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Technology and Code.
Keywords: Heart Failure, Genetic Therapy, Cardiotoxicity, Ventricular remodeling, Integrative Oncology, Transporters
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
